Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsFRA:QDI +1.43%73 Debt-to-EBITDA is 2.55 as of Jun. 2026, which is 7% below its 10-year median of 2.75. GuruFocus rates FRA:QDI with a GF Score™ of 73/100 and a GF Value™ of €168.90 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Quest Diagnostics ranks worse than 56.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Quest Diagnostics's Debt-to-EBITDA or its related term are showing as below:
FRA:QDI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.51 Med: 2.75 Max: 3.74
Current: 2.83
During the past 13 years, the highest Debt-to-EBITDA Ratio of Quest Diagnostics was 3.74. The lowest was 1.51. And the median was 2.75.
FRA:QDI's Debt-to-EBITDA is ranked worse than 56.14% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs FRA:QDI: 2.83
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Quest Diagnostics Debt-to-EBITDA Related Terms
Quest Diagnostics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QDI vs LH, MTD, ILMN: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Quest Diagnostics (FRA:QDI) has a Debt-to-EBITDA of 2.55 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Quest Diagnostics. This is near median its historical median of 2.75. Over the past decade, Quest Diagnostics' Debt-to-EBITDA has ranged from 1.51 to 3.74. According to the industry distribution chart, Quest Diagnostics ranks #64 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 56.1%.
Is Quest Diagnostics' Debt-to-EBITDA too high?
Quest Diagnostics' current Debt-to-EBITDA of 2.55 is near median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 3.74. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.32. Quest Diagnostics' value of 2.55 is 9.9% above this industry median. Based on the distribution chart, Quest Diagnostics ranks #64 out of 114 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Debt-to-EBITDA compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #64 out of 114 companies for Debt-to-EBITDA. This places Quest Diagnostics in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. Quest Diagnostics' value of 2.55 is 9.9% above this benchmark. Historically, Quest Diagnostics' own Debt-to-EBITDA has ranged from 1.51 to 3.74 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 2.32, Quest Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current Debt-to-EBITDA of 2.55 is 9.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Quest Diagnostics. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current Debt-to-EBITDA is 2.55, which is near median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €168.90, compared to a current price of €206.00 — trading 22% above its estimated fair value. The current Debt-to-EBITDA is 2.55, which is near median its 10-year median of 2.75 and 9.9% above the Medical Diagnostics & Research industry median of 2.32. Quest Diagnostics' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current Debt-to-EBITDA is 2.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €206.00 is trading 22% above its estimated GF Value™ of €168.90.
GuruFocus considers Quest Diagnostics to be Modestly Overvalued.
Key valuation signals for FRA:QDI:
Debt-to-EBITDA: 2.55 (near median its 10-year median of 2.75)
GF Value™: €168.90 vs. price of €206.00 (22% above fair value)
Industry Position: 9.9% above the Medical Diagnostics & Research median (#64 of 114)
No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
73GF Score
Get the complete analysis for FRA:QDI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QDI has been successfully added to your 
